Optical engine and an image projector having the optical engine
    1.
    发明申请
    Optical engine and an image projector having the optical engine 审中-公开
    光学引擎和具有光学引擎的图像投影仪

    公开(公告)号:US20060078266A1

    公开(公告)日:2006-04-13

    申请号:US11188183

    申请日:2005-07-22

    IPC分类号: G02B6/10

    摘要: An optical engine for an image projector comprises a light source, a taper rod, at least one light condenser, a prism module, a Digital Micromirror Device (DMD) and a projection lens set. One end of the taper rod is adjacent to the light source. Light generated by the light source is guided by the taper rod following a light path. The taper rod has increasing sizes of cross-sections along the light path, so as to decrease the dispersion angle of light, make the light more uniform, and increase the brightness of light. The prism module includes a first prism having a right triangle cross-section and a second prism having a wedge cross-section. The prism module receives the light from the condenser, passes the light toward the DMD, receives the light reflected by the DMD, and then passes the reflected light toward the projection lens set. The projection lens set projects the light on an external projection plane.

    摘要翻译: 用于图像投影仪的光学引擎包括光源,锥形杆,至少一个光聚光器,棱镜模块,数字微镜器件(DMD)和投影透镜组。 锥形杆的一端与光源相邻。 由光源产生的光由沿着光路的锥形杆引导。 锥形杆具有沿着光路的横截面增大的尺寸,以减小光的色散角,使光线更均匀,并增加光的亮度。 棱镜模块包括具有直角三角形横截面的第一棱镜和具有楔形横截面的第二棱镜。 棱镜模块接收来自聚光器的光,将光朝向DMD传递,接收由DMD反射的光,然后使反射光朝向投影透镜组。 投影透镜组将光投射到外部投影平面上。

    Metasurface skin cloak
    2.
    发明授权

    公开(公告)号:US10883799B1

    公开(公告)日:2021-01-05

    申请号:US14999918

    申请日:2016-12-13

    IPC分类号: H01Q15/02 F41H3/02 H01Q17/00

    摘要: This disclosure provides systems, methods, and devices related to a metasurface skin cloak. In one aspect, a metasurface skin cloak includes a dielectric layer and a plurality of blocks disposed on the dielectric layer. The dielectric layer is disposed over a surface including a feature on the surface. Each block of the plurality of blocks has a shape that is symmetric about two perpendicular axes. The metasurface skin can render the feature on the surface not optically detectable.

    NANOPORE DEVICES FOR SENSING BIOMOLECULES
    3.
    发明申请

    公开(公告)号:US20180280968A1

    公开(公告)日:2018-10-04

    申请号:US15945717

    申请日:2018-04-04

    摘要: The present disclosure provides chips, devices and methods for sequencing a biomolecule. The biomolecule may be DNA, RNA. a protein, or a peptide. The chip comprises a substrate; a first and second fluid chamber; fluid channels connecting the first and second fluid chamber; a first and second electrode disposed on opposing sides of the central fluid channel and having a nanogap therebetween, wherein the width of the nanogap is modulated by confined electrochemical deposition; and a passivation layer disposed on top of the first and second electrodes and the fluid channel.

    Federation of multi-level master data management systems
    6.
    发明授权
    Federation of multi-level master data management systems 失效
    多级主数据管理系统联合会

    公开(公告)号:US08635249B2

    公开(公告)日:2014-01-21

    申请号:US13117370

    申请日:2011-05-27

    IPC分类号: G06F17/30

    CPC分类号: G06F17/30286 G06F17/30566

    摘要: Federating multiple-level master data management systems may include a first set of master data management nodes having one or more common characteristics. A first group master data management node may be assigned to centrally manage the first set of master data management nodes, the first group master data management node maintaining master data management functionalities at a group level and providing a single logical view of master data to the first set of master data management nodes. Each master data management node in the first set has data access link with the first group master data management node based on implementation style of said each master data management node.

    摘要翻译: 联合多级主数据管理系统可以包括具有一个或多个共同特征的第一组主数据管理节点。 可以分配第一组主数据管理节点以集中管理第一组主数据管理节点,第一组主数据管理节点维护组级别的主数据管理功能,并将主数据的单个逻辑视图提供给第一组主数据管理节点 主数据管理节点集。 基于所述每个主数据管理节点的实现风格,第一组中的每个主数据管理节点与第一组主数据管理节点具有数据访问链路。

    S-5-SUBSTITUENT-N-2'-(THIOPHENE-2-YL)ETHYL-TETRALIN-2-AMINE OR CHIRAL ACID SALTS THEREOF AND USE FOR PREPARING ROTIGOTINE
    7.
    发明申请
    S-5-SUBSTITUENT-N-2'-(THIOPHENE-2-YL)ETHYL-TETRALIN-2-AMINE OR CHIRAL ACID SALTS THEREOF AND USE FOR PREPARING ROTIGOTINE 有权
    S-5-替代N-2' - (噻吩-2-基)乙基 - 四环素-2-胺或其酸性酸盐及其制备ROTIGOTINE的用途

    公开(公告)号:US20130046100A1

    公开(公告)日:2013-02-21

    申请号:US13394614

    申请日:2010-09-07

    IPC分类号: C07D333/20 C07D333/22

    CPC分类号: C07D333/20 C07B57/00

    摘要: The chiral compound S-5-substituted-N-2′-(thienyl-2-yl-)ethyl-tetralin-2-amine or its chiral acid salts and preparation method thereof are disclosed, and the method for preparing Rotigotine by using the chiral compound is also disclosed. Racemic 5-substituted-N-2′-(thien-2-yl-)ethyl-tetralin-2-amine (compound 1) is resolved by using a conventional chiral acid to obtain an optically pure chiral acid salt of S-5-substituted-N-2′-(thien-2-yl-)ethyl-tetralin-2-amine, which is then dissociated to obtain S-5-substituted-N-2′-(thien-2-yl-)ethyl-tetralin-2-amine (compound 2). The compound 2 or chiral acid salt thereof is alkylated and deprotected to produce rotigotine (compound 5).

    摘要翻译: 公开了手性化合物S-5-取代-N-2' - (噻吩基-2-基) - 乙基 - 四氢化萘-2-胺或其手性酸盐及其制备方法, 还公开了手性化合物。 通过使用常规的手性酸来拆分外消旋的5-取代的N-2' - (噻吩-2-基)乙基 - 四氢化萘-2-胺(化合物1),得到光学纯的手性酸S-5- 取代的N-2' - (噻吩-2-基)乙基 - 四氢化萘-2-胺,然后将其解离得到S-5-取代的N-2' - (噻吩-2-基) 四氢化萘-2-胺(化合物2)。 将化合物2或其手性酸式盐进行烷基化和脱保护,得到罗替戈汀(化合物5)。

    miRNAS AS THERAPEUTIC TARGETS IN CANCER
    9.
    发明申请
    miRNAS AS THERAPEUTIC TARGETS IN CANCER 审中-公开
    miRNA作为癌症中的治疗目标

    公开(公告)号:US20120087992A1

    公开(公告)日:2012-04-12

    申请号:US13257836

    申请日:2010-03-22

    摘要: Methods for modulating expression of a component of a cell, comprising contacting the cell with a nucleic acid comprising an miR-140 nucleic acid sequence in an amount sufficient to modulate the cellular component are provided. Overexpression of miR-140 inhibits cell proliferation in both U-2 OS (wt-p53) and HCT 116 (wt-p53) cell lines. Cells transfected with miR-140 are more resistant to chemotherapeutic agent methotrexate, mi-140 expression is related to HDAC4 protein expression. The claimed methods reduce the protein expression level of HDAC4 without degrading the target mRNA.

    摘要翻译: 提供了调节细胞成分表达的方法,包括使细胞与含有足以调节细胞成分的量的miR-140核酸序列的核酸接触。 miR-140的过表达抑制U-2 OS(wt-p53)和HCT 116(wt-p53)细胞系中的细胞增殖。 用miR-140转染的细胞对化学治疗剂甲氨蝶呤更具抗性,mi-140表达与HDAC4蛋白表达有关。 所要求的方法降低HDAC4的蛋白质表达水平,而不降解靶mRNA。